Events › 2017
BIO International Convention, San Diego, CA US
GenSight will attend and host partnering meetings.
2017 ARVO Annual Meeting, Baltimore, Maryland (US)
GenSight will attend the annual meeting 2017 ARVO.
American Academy of Neurology 69th Annual Meeting (AAN)
GenSight will give an oral presentation entitled "Intravitreal rAAV2/2-ND4 (GS010): A gene therapy for vision loss in Leber's Hereditary Optic Neuropathy (LHON) caused by the G11778A ND4 mitochondrial mutation" (Abstract number #2444) in Session S26: Neuro-ophthalmology/Neuro-Otology on April 25, 2017, at 4:18 PM (platform presentation number 005).
43rd NANOS Annual Meeting (North American Neuro-Ophthalmology Society)
GenSight will give an oral presentation and present two posters on its lead product GS010 currently in Phase 3 in Europe and US aiming at treating LHON, a rare mitochondrial genetic disease
Both posters will be presented at the session “Poster Session II: Scientific Advancements in Neuro-Ophthalmology” in the Category: Disorders of the Anterior Visual Pathway (Retina, Optic Nerve, and Chiasm) on Tuesday, April 4, 2017 from 6:00 -9:30 pm, Room Location: Exhibit Hall C
Title: Pediatric Leber Hereditary Optic Neuropathy (LHON): A Literature Review (Poster Number # 186)
Title: Preliminary Baseline Characteristics of Patients with LHON Enrolled in RESCUE and REVERSE Gene Therapy Trials (Poster Number # 189)
Presentation will take place on Tuesday, April 4th from 10:00am- 10:15am, in the Thurgood Marshall Ballroom
Title: Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4, Investigational Gene Therapy for ND4 LHON.
JP Morgan 35th Annual Healthcare Conference, San Francisco (CA), USA
Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings. GenSight took this opportunity to meet with a numerous partners and companies.
Oddo 20th Forum – Lyon, France
Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer hosted investor meetings at the 20th Oddo Forum in Lyon, France on January 5-6, 2017